Shipping to United States We Offer Worldwide Shipping
Login Wishlist

Methyl eugenol

$52

  • Brand : BIOFRON

  • Catalogue Number : BD-D1223

  • Specification : 98%(HPLC)

  • CAS number : 93-15-2

  • Formula : C11H14O2

  • Molecular Weight : 178.23

  • PUBCHEM ID : 7127

  • Volume : 20MG

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-D1223

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

178.23

Appearance

Colorless liquid

Botanical Source

Asarum sieboldii Miq/Present in many essential oils, e.g. nutmeg, mace and also many fruits, e.g. apple, banana, orange juice or peel, grapefruit, bilberry

Structure Type

Simple Phenylpropanoids

Category

Standards;Natural Pytochemical;API

SMILES

COC1=C(C=C(C=C1)CC=C)OC

Synonyms

1U2R CO1 DO1/methyl eugenol/4-Allylveratrole/1,2-dimethoxy-4-(2-propen-1-yl)benzene/1,3,4-eugenol methyl ether/O-Methyl eugenol/LEVO-ROSE OXIDE/Eugenol methyl ether/4-Allyl-1,2-dimethoxybenzene/3,4-dimethoxyallylbenzene/3-METHYLEUGENOL/1-allyl-3,4-dimethoxybenzene/Allyl veratrole/O-Methyleugenol/Eugenyl methyl ether/1,2-dimethoxy-4-(prop-2-en-1-yl)benzene/Methyleugenol/Benzene, 1,2-dimethoxy-4-(2-propen-1-yl)-/1-(3,4-Dimethoxyphenyl)-2-propene/4-Allylveratrol

IUPAC Name

1,2-dimethoxy-4-prop-2-enylbenzene

Applications

Density

1.0±0.1 g/cm3

Solubility

Methanol

Flash Point

87.1±22.7 °C

Boiling Point

254.7±0.0 °C at 760 mmHg

Melting Point

−4 °C(lit.)

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2909300000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:93-15-2) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31848500

Abstract

OBJECTIVE:
To observe the effect of methyl eugenol on the expression of aquaporin (AQP) 5 in nasal mucosa of rats with allergic rhinitis and to explore its significance.

METHODS:
In the study, 128 Wistar rats were randomly divided into normal control group, AR model control group, budesonide positive control group, 80 mg/kg group, 40 mg/kg group, 20 mg/kg group and 10 mg/kg group, and ovalbumin (OVA) was used to establish the model of allergic rhinitis. After successful modeling, castor oil, budesonide and corresponding doses of methyl eugenol were given respectively. After 1, 2 and 4 weeks of administration, the distribution of AQP5 in nasal mucosa was observed by immunohistochemistry. The expression of AQP5 in nasal mucosa of each group was compared by Western blotting. The expression of AQP5 mRNA was compared with real-time PCR.

RESULTS:
AQP5 was mainly located in the glandular epithelium and ductal epithelial cell membrane and cytoplasm. The expression of AQP5 and AQP5 mRNA in nasal mucosa of the rats in the model control group was lower than that in the normal control group (P<0.05). AQP5 and AQP5 mRNA in nasal mucosa of the rats in each treatment group were higher than those in the model control group in varying degrees. The expression of AQP5 in the budesonide group was not significantly different from that in the normal control group 1, 2 and 4 weeks after drug intervention (P>0.05), but there was significant difference between the budesonide group and the model control group (P<0.05). The expression of AQP5 mRNA in the budesonide group was significantly different from that in the normal control group and the model control group (P<0.05).After 2 weeks of intervention, the expression of AQP5 in each dose group of methyleugenol was not significantly different from that in the budesonide group (P>0.05). After 1 week of intervention, there was no significant difference in AQP5 mRNA between the 20 mg/kg group and the normal control group (P>0.05), but there was significant difference between the 20 mg/kg group and the model control group (P<0.05). CONCLUSION: Methyl eugenol may increase the degree of edema of the nasal mucosa by reducing the expression of AQP5 and reduce the secretion of glands, thus alleviating the symptoms of allergic rhinitis, sneezing and runny nose.

Title

[Effect of methyl eugenol on nasal mucosal aquaporin 5 in rats with allergic rhinitis].

Author

Wu N1, Zhang XL1, Hou Y2, Lin LX3, Zhang XB2.

Publish date

2019 Dec 18

PMID

31190651

Abstract

Two major fruit fly pest species, Bactrocera dorsalis and B. umbrosa, are strongly attracted to methyl eugenol (ME) found in >450 plant species. They are, however, exclusive pollinators of certain daciniphilous (attracting Dacini fruit flies) Bulbophyllum orchids. A comparison between the recaptures of feral males after feeding ad libitum on 0.6 mg ME (simulating an average floral quantity of an orchid flower – Trial 1) and 480 mg in Trial 2 was investigated using the non-invasive capture-mark-release-recapture (CMRR) technique. Based on daily CMRR over a 16-day period, using a different colour enamel paint each day, percentages of B. dorsalis males recaptured in Trial 1 were significantly higher than those in Trial 2. However, for B. umbrosa, percentages of recaptures for different day-specific colours were highly variable due to low fly numbers captured/day. In Trial 1, of 756 B. dorsalis males released, 36.4% were recaptured once, 7.7 twice, 2.4 three times and 0.4 four times. While in Trial 2 of 1157 released males, 6% were recaptured once and 0.3% twice. Of 67 B. umbrosa males released, 28.4% were recaptured once and none more than once in Trial 1. Nevertheless, of 119 flies released in Trial 2, 25.2% were recaptured once and 3.3% twice. Overall, many marked males did return to a single ME-source to ‘refuel’ ME (a sex pheromone precursor). The results also show that a relatively high number of flies paid multi-visitations to a single 0.6 mg ME-source and indicate that the presence of natural ME-sources may impact area-wide IPM programmes.

KEYWORDS

Dacini fruit flies; capture-mark-release-recapture; feral males; methyl eugenol; recaptures

Title

Recaptures of feral Bactrocera dorsalis and B. umbrosa (Diptera: Tephritidae) males after feeding on methyl eugenol.

Author

Tan KH1,2.

Publish date

2020 Feb

PMID

31172602

Abstract

BACKGROUND:
Ventricular tachycardia (VT) is one of the main predictors of mortality in Chagas cardiomyopathy (CC). Although the substrate of sustained and nonsustained-VT (NS-VT) seems to be the same, little is known about the distribution of late enhancement (LE). Our aim was to compare the clinical findings and the amount and patterns of LE in Chagas disease according to the presence and type of VT.

METHODS AND RESULTS:
Magnetic resonance imaging was performed in 54 Chagas seropositive patients: 8 indeterminate and 46 with CC of whom 15 were without VT, 13 with NS-VT, and 18 with sustained-VT (S-VT). There were 31 males (57%), mean age was 55.9 ± 12.2 years. LE was found in 87% of all patients and in 50%, 80%, and 100% of the indeterminate, without VT and VT groups, respectively. The percentage of LE increased progressively in the indeterminate, CC without VT, and CC with VT groups; without a significant difference between NS-VT and S-VT (0.93%, 15.2%, 23.2%, and 21.4%, respectively). The amount of LE increased with the functional class. LE in the basal and mid lateral wall was more frequent in VT, without difference between S-VT and NS-VT. The only predictor of VT was the percentage of LE, odds ratio (OR), 6.2; (95% confidence interval [CI], 3.7-28.4; P = .01) with a cutoff of Odds Ratio 17.1%.

CONCLUSIONS:
The amount of LE increases in relation to the clinical stage of the disease and its functional class in Chagas seropositive patients. The amount of LE was the main predictor of VT, without difference between S-VT and NS-VT.

© 2019 Wiley Periodicals, Inc.

KEYWORDS

Chagas disease; late enhancement; nonsustained ventricular tachycardia and sustained ventricular tachycardia; ventricular tachycardia

Title

Comparison of the amount and patterns of late enhancement in Chagas disease according to the presence and type of ventricular tachycardia.

Author

Melendez-Ramirez G1, Soto ME2, Velasquez Alvarez LC3, Meave A1, Juarez-Orozco LE4,5, Guarner-Lans V6, Morales JL7.

Publish date

2019 Sep